Cargando…

Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost

OBJECTIVE: Overactive bladder (OAB) affects 16.9% of women in the United States. Percutaneous tibial nerve stimulation (PTNS) is a third-line treatment for patients who are refractory to behavioral and pharmacologic therapies. We aimed to evaluate the effects of PTNS on urinary symptoms in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurdoğlu, Zehra, Carr, Danielle, Harmouche, Jihad, Ünlü, Serdar, Kılıç, Gökhan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838781/
https://www.ncbi.nlm.nih.gov/pubmed/29503256
http://dx.doi.org/10.4274/jtgga.2017.0115
_version_ 1783304304247963648
author Kurdoğlu, Zehra
Carr, Danielle
Harmouche, Jihad
Ünlü, Serdar
Kılıç, Gökhan S.
author_facet Kurdoğlu, Zehra
Carr, Danielle
Harmouche, Jihad
Ünlü, Serdar
Kılıç, Gökhan S.
author_sort Kurdoğlu, Zehra
collection PubMed
description OBJECTIVE: Overactive bladder (OAB) affects 16.9% of women in the United States. Percutaneous tibial nerve stimulation (PTNS) is a third-line treatment for patients who are refractory to behavioral and pharmacologic therapies. We aimed to evaluate the effects of PTNS on urinary symptoms in patients diagnosed as having refractory OAB and investigate the cost of medications and clinical visits before and after PTNS treatment. MATERIAL AND METHODS: We reviewed 60 women with refractory OAB treated with PTNS. Episodes of urinary frequency, leakage, urgency, and nocturia; number of follow-up visits; and medications were recorded. The mean quarterly drug, physician, nurse, and provider costs were calculated. The episodes of urinary symptoms, numbers of follow-up visits, and costs of medications and visits before and after PTNS were compared. RESULTS: Of the 60 patients with refractory OAB, 24 patients who completed 12 weekly sessions of initial PTNS were evaluated. The number of urinary symptoms and follow-up visits significantly decreased after PTNS (p<0.05). The average quarterly medication cost decreased from $656.36±292.45 to $375.51±331.79 after PTNS (p=0.001). After PTNS, quarterly physician and nurse visit costs decreased from $81.73±70.39 to $25.89±54.40 and from $55.23±38.32 to $15.53±19.58, respectively (p<0.05). The quarterly total provider cost was similar before and after PTNS. CONCLUSION: PTNS treatment significantly improved urinary symptoms of patients with refractory OAB and reduced the costs of medications and physician and nurse visits.
format Online
Article
Text
id pubmed-5838781
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-58387812018-03-08 Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost Kurdoğlu, Zehra Carr, Danielle Harmouche, Jihad Ünlü, Serdar Kılıç, Gökhan S. J Turk Ger Gynecol Assoc Original Investigation OBJECTIVE: Overactive bladder (OAB) affects 16.9% of women in the United States. Percutaneous tibial nerve stimulation (PTNS) is a third-line treatment for patients who are refractory to behavioral and pharmacologic therapies. We aimed to evaluate the effects of PTNS on urinary symptoms in patients diagnosed as having refractory OAB and investigate the cost of medications and clinical visits before and after PTNS treatment. MATERIAL AND METHODS: We reviewed 60 women with refractory OAB treated with PTNS. Episodes of urinary frequency, leakage, urgency, and nocturia; number of follow-up visits; and medications were recorded. The mean quarterly drug, physician, nurse, and provider costs were calculated. The episodes of urinary symptoms, numbers of follow-up visits, and costs of medications and visits before and after PTNS were compared. RESULTS: Of the 60 patients with refractory OAB, 24 patients who completed 12 weekly sessions of initial PTNS were evaluated. The number of urinary symptoms and follow-up visits significantly decreased after PTNS (p<0.05). The average quarterly medication cost decreased from $656.36±292.45 to $375.51±331.79 after PTNS (p=0.001). After PTNS, quarterly physician and nurse visit costs decreased from $81.73±70.39 to $25.89±54.40 and from $55.23±38.32 to $15.53±19.58, respectively (p<0.05). The quarterly total provider cost was similar before and after PTNS. CONCLUSION: PTNS treatment significantly improved urinary symptoms of patients with refractory OAB and reduced the costs of medications and physician and nurse visits. Galenos Publishing 2018-03 2018-03-01 /pmc/articles/PMC5838781/ /pubmed/29503256 http://dx.doi.org/10.4274/jtgga.2017.0115 Text en ©Copyright 2018 by the Turkish-German Gynecological Education and Research Foundation http://creativecommons.org/licenses/by/2.5/ Journal of the Turkish-German Gynecological Association
spellingShingle Original Investigation
Kurdoğlu, Zehra
Carr, Danielle
Harmouche, Jihad
Ünlü, Serdar
Kılıç, Gökhan S.
Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost
title Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost
title_full Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost
title_fullStr Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost
title_full_unstemmed Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost
title_short Short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost
title_sort short-term results of the efficacy of percutaneous tibial nerve stimulation on urinary symptoms and its financial cost
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838781/
https://www.ncbi.nlm.nih.gov/pubmed/29503256
http://dx.doi.org/10.4274/jtgga.2017.0115
work_keys_str_mv AT kurdogluzehra shorttermresultsoftheefficacyofpercutaneoustibialnervestimulationonurinarysymptomsanditsfinancialcost
AT carrdanielle shorttermresultsoftheefficacyofpercutaneoustibialnervestimulationonurinarysymptomsanditsfinancialcost
AT harmouchejihad shorttermresultsoftheefficacyofpercutaneoustibialnervestimulationonurinarysymptomsanditsfinancialcost
AT unluserdar shorttermresultsoftheefficacyofpercutaneoustibialnervestimulationonurinarysymptomsanditsfinancialcost
AT kılıcgokhans shorttermresultsoftheefficacyofpercutaneoustibialnervestimulationonurinarysymptomsanditsfinancialcost